MA53983A - Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb - Google Patents
Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhbInfo
- Publication number
- MA53983A MA53983A MA053983A MA53983A MA53983A MA 53983 A MA53983 A MA 53983A MA 053983 A MA053983 A MA 053983A MA 53983 A MA53983 A MA 53983A MA 53983 A MA53983 A MA 53983A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- treatment
- member heteroaryl
- carboxamide compounds
- heteroaryl carboxamide
- Prior art date
Links
- -1 CARBOXAMIDE COMPOUNDS Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748906P | 2018-10-22 | 2018-10-22 | |
| US201962858790P | 2019-06-07 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53983A true MA53983A (fr) | 2021-12-15 |
Family
ID=68610300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053983A MA53983A (fr) | 2018-10-22 | 2019-10-22 | Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11560370B1 (https=) |
| EP (1) | EP3870296A1 (https=) |
| JP (1) | JP2022508953A (https=) |
| KR (1) | KR20210095143A (https=) |
| CN (1) | CN113195055A (https=) |
| AU (1) | AU2019364352A1 (https=) |
| BR (1) | BR112021007602A2 (https=) |
| CA (1) | CA3117449A1 (https=) |
| IL (1) | IL282433A (https=) |
| MA (1) | MA53983A (https=) |
| MX (1) | MX2021004580A (https=) |
| PH (1) | PH12021550887A1 (https=) |
| SG (1) | SG11202104086PA (https=) |
| TW (1) | TW202028190A (https=) |
| WO (1) | WO2020086533A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205264A (zh) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | 一种合成同位羟基和甲磺酰甲基化合物的新方法 |
| US20230295096A1 (en) * | 2020-04-22 | 2023-09-21 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| CA3180706A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| JP2023551474A (ja) * | 2020-11-25 | 2023-12-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の処置および予防のための芳香族架橋環アミド誘導体 |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| CN118339163A (zh) * | 2021-10-20 | 2024-07-12 | 组装生物科学股份有限公司 | 新的晶型 |
| WO2023105481A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
| EP4665330A1 (en) * | 2023-02-17 | 2025-12-24 | Merck Sharp & Dohme LLC | Plasma kallikrein inhibitors |
| KR102827002B1 (ko) * | 2023-06-28 | 2025-06-30 | 국립순천대학교산학협력단 | 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물 |
| WO2025029961A1 (en) * | 2023-07-31 | 2025-02-06 | Makscientific, Llc | Pharmaceutical compositions, and preparation and methods of use thereof |
| CN117603089A (zh) * | 2023-11-29 | 2024-02-27 | 南通瑞合达医药科技有限公司 | 一种环戊腈的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1435948A1 (en) * | 2001-08-06 | 2004-07-14 | Pharmacia Italia S.p.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| WO2008130584A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| PE20121118A1 (es) * | 2009-05-12 | 2012-09-05 | Romark Lab Lc | Compuestos de haloalquil heteroaril benzamida |
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| EA026977B1 (ru) | 2012-01-06 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA038942B1 (ru) | 2012-08-28 | 2021-11-12 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
| MX2015002954A (es) | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
| CA2889892A1 (en) | 2012-11-09 | 2014-05-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| CA2892606A1 (en) | 2012-12-06 | 2014-06-12 | Baruch S. Blumberg Institute | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| CN105209031A (zh) | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
| HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| CN105209470B (zh) | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| EA035500B1 (ru) * | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| AU2014348518B2 (en) * | 2013-11-14 | 2019-01-03 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EP3271019A1 (en) * | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| CN105503730B (zh) * | 2015-12-25 | 2018-06-22 | 山东大学 | 吡唑类衍生物及其制备方法与应用 |
| UY37581A (es) * | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| CN108250112B (zh) * | 2018-01-30 | 2019-08-27 | 西北大学 | 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法 |
-
2019
- 2019-10-22 TW TW108138129A patent/TW202028190A/zh unknown
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/es unknown
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 CA CA3117449A patent/CA3117449A1/en active Pending
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/ja active Pending
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/pt not_active IP Right Cessation
- 2019-10-22 MA MA053983A patent/MA53983A/fr unknown
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/en not_active Ceased
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/zh active Pending
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/en not_active Withdrawn
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/ko not_active Withdrawn
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en not_active Abandoned
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US12030869B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019364352A1 (en) | 2021-06-03 |
| US12030869B2 (en) | 2024-07-09 |
| KR20210095143A (ko) | 2021-07-30 |
| EP3870296A1 (en) | 2021-09-01 |
| BR112021007602A2 (pt) | 2021-07-27 |
| WO2020086533A1 (en) | 2020-04-30 |
| SG11202104086PA (en) | 2021-05-28 |
| US20240150324A1 (en) | 2024-05-09 |
| CN113195055A (zh) | 2021-07-30 |
| JP2022508953A (ja) | 2022-01-19 |
| PH12021550887A1 (en) | 2022-02-21 |
| MX2021004580A (es) | 2021-09-08 |
| CA3117449A1 (en) | 2020-04-30 |
| IL282433A (en) | 2021-06-30 |
| TW202028190A (zh) | 2020-08-01 |
| US11560370B1 (en) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53983A (fr) | Composés d'hétéroaryle carboxamide à 5 chaînons pour le traitement du vhb | |
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| EP3675859A4 (en) | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES | |
| EP3935050A4 (en) | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | |
| EP3790867A4 (en) | KDM1A INHIBITORS FOR DISEASE TREATMENT | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| EP3405183A4 (en) | ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| EP3704108A4 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGICAL DISORDERS | |
| EP3455205A4 (en) | PEPTIDOMIMETICS FOR TREATING A NOVOVIRUS INFECTION | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| EP3374350A4 (en) | HYDROXYPYRIDINONE- AND HYDROXYPYRIMIDINONE-BASED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| EP3737361A4 (en) | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES | |
| EP3445352A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS DISEASES | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| EP3432892A4 (en) | USEFUL MANNOSE-DERIVED ANTAGONISTS FROM FIMH FOR THE TREATMENT OF DISEASES | |
| EP3504204A4 (en) | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES | |
| EP3743091A4 (en) | PROCEDURES AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS | |
| EP3655404A4 (en) | COMPOUNDS AND THEIR USE TO TREAT MICROBIAL INFECTIONS | |
| MA54313A (fr) | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl | |
| EP3634426A4 (en) | COMPOSITIONS FOR TREATMENT OF FIBROSE | |
| MA55973A (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
| EP3749322A4 (en) | Compounds and methods for treating addiction and related disorders | |
| EP3773221A4 (en) | TREATMENT OF HYDROCEPHALUS | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |